Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in North America, Europe, and the Asia Pacific. It operates in two segments, Medical, and Nuclear & Safety. The Medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as product handling, medical imaging furniture, and rehabilitation products. This segment improves the quality and safety of cancer care delivery; and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include radiation measurement and monitoring solutions, reactor instrumentation and control detectors, imaging systems and cameras, and waste management systems; laboratory and scientific analysis systems comprising gamma/alpha spectroscopy, alpha/beta counting, specialty detectors, and spectroscopy software; radiation measurement and health physics instrumentation; and contamination and clearance monitors. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.

Mirion Technologies Inc. Class A

The latest update is out from Mirrabooka Investments Ltd ( ($AU:MIR) ). Mirrabooka Investments Limited announced an estimated pre-tax net tangible ...

Mirrabooka Investments Reports Estimated NTA Backing

Mirum Pharmaceuticals (($MIRM)) has held its Q3 earnings call. Read on for the main highlights of the call. Mirum Pharmaceuticals’ latest earnings ...

Mirum Pharmaceuticals Reports Robust Q3 Growth and Milestones

Mirrabooka Investments Ltd ( ($AU:MIR) ) has issued an announcement. Mirrabooka Investments Limited, a company listed on the Australian Securities ...

Mirrabooka Investments Announces Estimated NTA Backing

Mirion Technologies, Inc. (($MIR)) has held its Q3 earnings call. Read on for the main highlights of the call. Mirion Technologies recently held it...

Mirion Technologies Shines in Nuclear Growth Amid Challenges

Mirion Technologies, Inc. ( ($MIR) ) has released its Q3 earnings. Here is a breakdown of the information Mirion Technologies, Inc. presented to it...

Mirion Technologies Reports Strong Q3 2025 Results

In a report released today, Jeff Grampp from Northland Securities maintained a Buy rating on Mirion Technologies, with a price target of $29.00. Th...

Northland Securities Remains a Buy on Mirion Technologies (MIR)

An announcement from Mirrabooka Investments Ltd ( ($AU:MIR) ) is now available. Mirrabooka Investments Limited announced its estimated net tangible...

MIRA Pharmaceuticals, Inc. ( ($MIRA) ) has provided an update. MIRA Pharmaceuticals has initiated the multiple ascending dose (MAD) phase of its Ph...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MIR	$23.80	+5.45%	5.39M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MIR	$23.80	+5.4%	5.39M
3
4
5
6

MIR

MIR

Get Mirion Technologies Inc. Class A Data in Excel

Get Mirion Technologies Inc. Class A Data in Excel